Figure 4
Figure 4. Use of anti-CMV antiviral therapy by type of prevention strategy. Anti-CMV therapy was considered ganciclovir and foscarnet; induction therapy was the period during which patients received the equivalent of twice-daily dosing of anti-CMV therapy. Only patients with proven CMV reactivation included. Total percentage was determined by days on anti-CMV therapy divided by total days alive during the first 100 days after transplantation. Whiskers equal 10th to 90th percentile, and solid dots equal outliers.

Use of anti-CMV antiviral therapy by type of prevention strategy. Anti-CMV therapy was considered ganciclovir and foscarnet; induction therapy was the period during which patients received the equivalent of twice-daily dosing of anti-CMV therapy. Only patients with proven CMV reactivation included. Total percentage was determined by days on anti-CMV therapy divided by total days alive during the first 100 days after transplantation. Whiskers equal 10th to 90th percentile, and solid dots equal outliers.

Close Modal

or Create an Account

Close Modal
Close Modal